Identification of ovarian cancer associated genes using an integrated approach in a Boolean framework

BackgroundCancer is a complex disease where molecular mechanism remains elusive. A systems approach is needed to integrate diverse biological information for the prognosis and therapy risk assessment using mechanistic approach to understand gene interactions in pathways and networks and functional attributes to unravel the biological behaviour of tumors.ResultsWe weighted the functional attributes based on various functional properties observed between cancerous and non-cancerous genes reported from literature. This weighing schema was then encoded in a Boolean logic framework to rank differentially expressed genes. We have identified 17 genes to be differentially expressed from a total of 11,173 genes, where ten genes are reported to be down-regulated via epigenetic inactivation and seven genes are up-regulated. Here, we report that the overexpressed genes IRAK1, CHEK1 and BUB1 may play an important role in ovarian cancer. We also show that these 17 genes can be used to form an ovarian cancer signature, to distinguish normal from ovarian cancer subjects and that the set of three genes, CHEK1, AR, and LYN, can be used to classify good and poor prognostic tumors.ConclusionWe provided a workflow using a Boolean logic schema for the identification of differentially expressed genes by integrating diverse biological information. This integrated approach resulted in the identification of genes as potential biomarkers in ovarian cancer.

[1]  Akhilesh Pandey,et al.  Human Protein Reference Database and Human Proteinpedia as discovery tools for systems biology. , 2009, Methods in molecular biology.

[2]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[3]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[4]  Lokesh P. Tripathi,et al.  TargetMine, an Integrated Data Warehouse for Candidate Gene Prioritisation and Target Discovery , 2011, PloS one.

[5]  Q. Cui,et al.  Identification of high-quality cancer prognostic markers and metastasis network modules , 2010, Nature communications.

[6]  K. Chung,et al.  Up‐regulation and clinical significance of serine protease kallikrein 6 in colon cancer , 2011, Cancer.

[7]  J. V. van Deursen,et al.  Bub1 overexpression induces aneuploidy and tumor formation through Aurora B kinase hyperactivation , 2011, The Journal of cell biology.

[8]  Gilles Landman,et al.  Cell adhesion and communication proteins are differentially expressed in melanoma progression model. , 2011, Human pathology.

[9]  Dennis B. Troup,et al.  NCBI GEO: archive for functional genomics data sets—10 years on , 2010, Nucleic Acids Res..

[10]  R. Shamir,et al.  Regulatory networks define phenotypic classes of human stem cell lines , 2008, Nature.

[11]  Jeffrey T. Chang,et al.  GATHER: a systems approach to interpreting genomic signatures , 2006, Bioinform..

[12]  Yun Dai,et al.  New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network , 2010, Clinical Cancer Research.

[13]  G. Glinsky.  "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Liekens,et al.  BioGraph: unsupervised biomedical knowledge discovery via automated hypothesis generation , 2011, Genome Biology.

[15]  C. Sander,et al.  The HUPO PSI's Molecular Interaction format—a community standard for the representation of protein interaction data , 2004, Nature Biotechnology.

[16]  Robert D. Finn,et al.  The Pfam protein families database , 2004, Nucleic Acids Res..

[17]  P. Laird,et al.  Discovery of multi-dimensional modules by integrative analysis of cancer genomic data , 2012, Nucleic acids research.

[18]  Leigh Murphy,et al.  Review Nuclear Receptor Signaling | The Open Access Journal of the Nuclear Receptor Signaling Atlas Post-translational modifications of nuclear receptors and human disease , 2011 .

[19]  Ingo Ruczinski,et al.  Identifying interacting SNPs using Monte Carlo logic regression , 2005, Genetic epidemiology.

[20]  Jolanta Lissowska,et al.  CHEK2, MGMT, SULT1E1 and SULT1A1 Polymorphisms and Endometrial Cancer Risk , 2011, Twin Research and Human Genetics.

[21]  Gabriela Kalna,et al.  Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. , 2010, The Journal of clinical investigation.

[22]  Kai Stoeber,et al.  Cdc7 Kinase Is a Predictor of Survival and a Novel Therapeutic Target in Epithelial Ovarian Carcinoma , 2009, Clinical Cancer Research.

[23]  K R Coombes,et al.  Cancer genomics: promises and complexities. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[25]  John C. Marshall,et al.  Dynamic Regulation of Neutrophil Survival through Tyrosine Phosphorylation or Dephosphorylation of Caspase-8* , 2008, Journal of Biological Chemistry.

[26]  Ole Mogensen,et al.  Reproducibility of mass spectrometry based protein profiles for diagnosis of ovarian cancer across clinical studies: A systematic review. , 2012, Journal of proteomics.

[27]  R. Berkowitz,et al.  Osteopontin as a potential diagnostic biomarker for ovarian cancer. , 2002, JAMA.

[28]  M. Page,et al.  Serine peptidases: Classification, structure and function , 2008, Cellular and Molecular Life Sciences.

[29]  A. Su,et al.  Applications of a rat multiple tissue gene expression data set. , 2004, Genome research.

[30]  Ioannis Xenarios,et al.  DIP: The Database of Interacting Proteins: 2001 update , 2001, Nucleic Acids Res..

[31]  D S Latchman,et al.  Transcription-factor mutations and disease. , 1996, The New England journal of medicine.

[32]  K. A. Walsh,et al.  [3] Serine proteases , 1970 .

[33]  A. Sakurada,et al.  Genome-wide profiling of promoter methylation in human , 2006, Oncogene.

[34]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[35]  Shuk-Mei Ho,et al.  Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells , 1999 .

[36]  W. Vach,et al.  Reproducibility of mass spectrometry based protein profiles for diagnosis of breast cancer across clinical studies: a systematic review. , 2008, Journal of proteome research.

[37]  Philippe Dessen,et al.  Atlas of Genetics and Cytogenetics in Oncology and Haematology, year 2003 , 2003, Nucleic Acids Res..

[38]  Don Gilbert,et al.  Biomolecular Interaction Network Database , 2005, Briefings Bioinform..

[39]  Tsippi Iny Stein,et al.  In-silico human genomics with GeneCards , 2011, Human Genomics.

[40]  I. Mills,et al.  The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. , 2013, Cancer cell.

[41]  Adam J. Smith,et al.  The Database of Interacting Proteins: 2004 update , 2004, Nucleic Acids Res..

[42]  Simo V. Zhang,et al.  A map of human cancer signaling , 2007, Molecular systems biology.

[43]  Ozlem Keskin,et al.  Human Cancer Protein-Protein Interaction Network: A Structural Perspective , 2009, PLoS Comput. Biol..

[44]  Holger Schwender,et al.  Logic regression and its extensions. , 2010, Advances in genetics.

[45]  C. Castro,et al.  [Insulin-like growth factor receptor I signaling in a breast cancer cell line]. , 2011, Biomedica : revista del Instituto Nacional de Salud.

[46]  L. Holm,et al.  The Pfam protein families database , 2005, Nucleic Acids Res..

[47]  Eran Segal,et al.  Stemness, cancer, and cancer stem cells , 2008, Cell cycle.

[48]  Sudhir Srivastava,et al.  Posttranslational Protein Modifications , 2006, Molecular & Cellular Proteomics.

[49]  J. H. Moore,et al.  Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. , 2001, American journal of human genetics.

[50]  A. Seth,et al.  ETS transcription factors and their emerging roles in human cancer. , 2005, European journal of cancer.

[51]  Susanta Roychoudhury,et al.  Inactivation of CHEK1 and EI24 is associated with the development of invasive cervical carcinoma: Clinical and prognostic implications , 2011, International journal of cancer.

[52]  Iver Petersen,et al.  IGFBP7 is a p53 target gene inactivated in human lung cancer by DNA hypermethylation. , 2011, Lung cancer.

[53]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[54]  Terence P. Speed,et al.  Sparse combinatorial inference with an application in cancer biology , 2009, Bioinform..

[55]  Arnaud Céol,et al.  3did: identification and classification of domain-based interactions of known three-dimensional structure , 2010, Nucleic Acids Res..

[56]  Carsten Wiuf,et al.  Tumor-specific usage of alternative transcription start sites in colorectal cancer identified by genome-wide exon array analysis , 2011, BMC Genomics.

[57]  Livia Perfetto,et al.  MINT, the molecular interaction database: 2009 update , 2009, Nucleic Acids Res..

[58]  S. Mok,et al.  Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[59]  Tsutomu Miyamoto,et al.  Immunohistochemical detection of a specific receptor for lipocalin2 (solute carrier family 22 member 17, SLC22A17) and its prognostic significance in endometrial carcinoma. , 2011, Experimental and molecular pathology.

[60]  Francisco S. Roque,et al.  A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes , 2008, Proceedings of the National Academy of Sciences.

[61]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[62]  Akihiko Kawahara,et al.  Expression of IGF-1 and IGF-1R and their relation to clinicopathological factors in colorectal cancer. , 2011, Anticancer research.

[63]  Constantine Kappas,et al.  Survivin regulation by HER2 through NF-κB and c-myc in irradiated breast cancer cells , 2011, Journal of cellular and molecular medicine.

[64]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[65]  Michael Q. Zhang,et al.  TRED: a transcriptional regulatory element database, new entries and other development , 2007, Nucleic Acids Res..

[66]  R. Berkowitz,et al.  Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. , 2001, Journal of the National Cancer Institute.

[67]  Chris Sander,et al.  Time to Recurrence and Survival in Serous Ovarian Tumors Predicted from Integrated Genomic Profiles , 2011, PloS one.

[68]  Antonio Reverter,et al.  A Boolean-based systems biology approach to predict novel genes associated with cancer: Application to colorectal cancer , 2011, BMC Systems Biology.

[69]  W. Scher,et al.  Serine proteases. , 1986, Science.

[70]  Y. Zhang,et al.  IntAct—open source resource for molecular interaction data , 2006, Nucleic Acids Res..

[71]  A. Butte,et al.  AILUN: reannotating gene expression data automatically , 2007, Nature Methods.

[72]  C. Wong,et al.  Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. , 2010, Experimental cell research.

[73]  Christie S. Chang,et al.  The BioGRID interaction database: 2013 update , 2012, Nucleic Acids Res..

[74]  Federica Rizzi,et al.  Molecular mechanisms of the antimetastatic activity of nuclear clusterin in prostate cancer cells. , 2011, International journal of oncology.

[75]  Rainer Breitling,et al.  Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments , 2004, FEBS letters.

[76]  Gábor Csárdi,et al.  The igraph software package for complex network research , 2006 .

[77]  C. Daub,et al.  BMC Systems Biology , 2007 .

[78]  Kara Dolinski,et al.  The BioGRID Interaction Database: 2011 update , 2010, Nucleic Acids Res..

[79]  Karin Jirström,et al.  Open Access RESEARCH , 2010 .

[80]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[81]  Kengo Kinoshita,et al.  Assessing the utility of gene co-expression stability in combination with correlation in the analysis of protein-protein interaction networks , 2011, BMC Genomics.

[82]  Karin Dahlman-Wright,et al.  Interplay between AP-1 and estrogen receptor α in regulating gene expression and proliferation networks in breast cancer cells. , 2012, Carcinogenesis.

[83]  Paul M. Magwene,et al.  Estimating genomic coexpression networks using first-order conditional independence , 2004, Genome Biology.

[84]  Chih-yuan Chiang,et al.  A Human MAP Kinase Interactome , 2010, Nature Methods.

[85]  Maria Victoria Schneider,et al.  MINT: a Molecular INTeraction database. , 2002, FEBS letters.

[86]  Ulrich Keller,et al.  Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells , 2011, Clinical Cancer Research.